MDS 2026 Debrief: Two Genetic Bets Fall in Full Data & Juvmo Meets Its Payers

<p>The Pharma Closeout&#39;s MDS 2026 Debrief covers the readouts from the International Parkinson and Movement Disorder Society congress in Seoul that matter for drug, diagnostic and payer strategy. Biogen and Denali&#39;sLUMA and Bial&#39;s ACTIVATE showed full data on two genetic bets in Parkinson&#39;s disease that missed, and we look at what still stands: Arvinas&#39;s LRRK2 degrader, a spinal-fluid marker that could help pick patients, and Roche&#39;s prasinezumab Phase 3. AbbVie&#39;s newly approved Juvmo meets ICER&#39;s numbers, and we put Cerevance&#39;s solengepras result against the approved add-ons. Plus Syntara&#39;s trial in REM sleep behaviour disorder, a skin test for alpha-synuclein, Praxis&#39;s essential tremor drug, Teva&#39;s ecopipam in Tourettesyndrome, Neurocrine&#39;s five-year valbenazine data, and what to watch: the Huntington&#39;s congress, ICER&#39;s final report, Austedo&#39;s Medicare price and Praxis&#39;s FDA date.</p><p><br></p><p>0:00 Cold open and introduction<br>1:02 Story of the Congress: two genetic bets fall in full data<br>4:03 The remaining bets: Arvinas&#39;s degrader, a spinal-fluid marker, Roche&#39;s prasinezumab<br>6:00 AbbVie&#39;s Juvmo meets ICER<br>8:11 Solengepras: how to read 37 minutes<br>9:48 Before diagnosis: Syntara&#39;s REM sleep trial and a skin test<br>11:48 Beyond Parkinson&#39;s: essential tremor, Tourette syndrome, Huntington&#39;s disease<br>14:15 What to watch: Huntington&#39;s congress, ICER&#39;s final report, Austedopricing, Praxis&#39;s FDA date</p><p>Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.</p><p></p>